Untitled
Apixmed Prism — an innovative next-generation genetic analytics platform
Home keyboard_arrow_right Blog keyboard_arrow_right
Men's Health: Which Checkups Really Matter and When to Get Them
Mens Health
Publication date:
8 minutes reading

Men's Health: Which Checkups Really Matter and When to Get Them

Smiling middle-aged man with a thick mustache wearing a light jacket on a city street, representing Movember.

Testosterone levels, prostate health, cardiovascular health and glucose metabolism — each of these affects a man's well-being, physical performance and health throughout life. Regular checkups in these key areas help not only to assess the body's current state but also to identify which important physiological markers need closer monitoring in order to stay healthy with age.

At the same time, different checkups have their own indications and recommended timing. Some markers need regular monitoring, while others should be checked after a certain age or when specific risk factors are present. Family history and genetic characteristics are also important for assessing individual susceptibility to certain diseases and setting prevention priorities.

From the Apixmed team:

This material is published in support of the global Movember movement, which aims to draw attention to important issues in men's health, cancer prevention and psychological well-being.

Checkups for men by health area

Prostate: when to test PSA

Prostate cancer is among the most common cancers in men. In 2022 it was diagnosed in about 1.5 million men worldwide, second in frequency only to lung cancer (Bray F et al., CA: A Cancer Journal for Clinicians, 2024). In the early stages it often causes no symptoms, so early detection matters especially after a certain age, and above all when additional risk factors are present.

The main laboratory marker used to assess the prostate is prostate-specific antigen (PSA) — a protein produced by prostate cells. PSA is measured in the blood, but an elevated level is not a specific sign of cancer: it can also occur with benign prostatic hyperplasia, inflammation and other conditions. A PSA result therefore cannot be interpreted separately from age, medical history and the clinical picture.

For men without known risk factors for prostate cancer, PSA screening is usually recommended from around age 50, after discussing whether it is appropriate with a doctor. If close relatives have had prostate cancer, or other risk factors are present, a doctor may order PSA screening earlier — from around age 40–45. For carriers of pathogenic variants in the BRCA2 (BRCA2 DNA repair associated) gene, European guidelines allow for early PSA testing from age 40 (Wei JT et al., The Journal of Urology, 2023; EAU Guidelines on Prostate Cancer, 2025).

An elevated PSA does not by itself confirm a cancer diagnosis. If needed, a doctor may recommend repeating the test, checking additional markers, magnetic resonance imaging or a biopsy.

Important! Urinary problems, blood in the urine or semen, and pain in the pelvis or perineum require a doctor's visit at any age. In that case it is no longer preventive screening but a diagnostic search for the cause of the symptoms.

Testosterone: when testing is needed

Testosterone affects sexual function, muscle and bone tissue, red blood cell production and a number of metabolic processes. Its level can change with age, but an age-related decline in the hormone does not in itself indicate hypogonadism and is not grounds for hormone therapy.

Testosterone testing is recommended when there are symptoms or clinical signs that may point to a deficiency, including persistent loss of libido, erectile dysfunction, fewer spontaneous morning erections, infertility, anemia of unclear origin and reduced bone density. Each of these symptoms can have other causes, so test results are assessed together with complaints, medical history and other clinical data.

For the initial assessment, doctors measure total testosterone in a fasting morning blood sample. If the result is below normal, it must be confirmed by a repeat measurement on another day. Hypogonadism is diagnosed when characteristic symptoms or clinical signs coincide with consistently low hormone levels (Bhasin S et al., The Journal of Clinical Endocrinology & Metabolism, 2018).

Routine testosterone testing in men without symptoms or other clinical indications is not recommended. Likewise, testosterone replacement therapy should not be started solely because of an age-related decline in the hormone or a wish to improve fitness, without a confirmed diagnosis of hypogonadism and an assessment of the possible risks of treatment.

For more on the link between genetics and hormones, including testosterone, see the article Somatotropin, estrogen and testosterone: how genetics relates to hormones.

Automatic digital blood pressure monitor with a grey cuff next to a glass cup of tea on a light blue table.

Checkups and tests for men that need regularity

Blood pressure

Arterial hypertension is one of the main modifiable risk factors for stroke, coronary heart disease, heart failure and chronic kidney disease. Its danger is that elevated pressure often causes no noticeable symptoms. A person can feel well for years without suspecting changes that gradually increase the load on the blood vessels and heart (US Preventive Services Task Force, JAMA, 2021).

The main way to detect hypertension is regular blood pressure measurement. According to USPSTF (United States Preventive Services Task Force) recommendations, adults aged 40 and older should be screened every year. With normal readings and no risk factors at a younger age, the intervals can be longer.

For a reliable result, sit quietly for at least five minutes before the measurement. The cuff should fit the circumference of the upper arm, and the arm should be at heart level. Several measurements per session are advisable: a single elevated reading is not enough for a diagnosis. If the results raise suspicion of hypertension, they are confirmed with measurements outside the doctor's office: home monitoring or 24-hour ambulatory blood pressure monitoring. This helps to distinguish sustained hypertension, white coat hypertension and masked hypertension (US Preventive Services Task Force, JAMA, 2021). With white coat hypertension, blood pressure rises only at the doctor's office, usually from anxiety. With masked hypertension it is the opposite: pressure is normal at the doctor's office but elevated at home or during the day.

Lipid profile and cardiovascular risk

Lipid metabolism disorders often have no outward signs but can speed up the development of atherosclerosis. A lipid panel is used to assess them, and it includes total cholesterol, low-density lipoprotein cholesterol (LDL, or “bad” cholesterol) and high-density lipoprotein cholesterol (HDL, or “good” cholesterol), as well as triglycerides.

Particular attention is paid to low-density lipoprotein cholesterol. Its elevated level promotes the buildup of cholesterol in artery walls and the formation of atherosclerotic plaques, which over time can narrow the vessels and increase the risk of myocardial infarction and stroke.

At the same time, lipid panel results should not be assessed in isolation. The LDL level and its target values are determined in light of overall cardiovascular risk, which is assessed from age, blood pressure, smoking status, diabetes, chronic kidney disease and a history of cardiovascular disease. Accordingly, the LDL target for a man with no established cardiovascular disease and for a man who has already had a myocardial infarction will differ (Visseren FLJ et al., European Heart Journal, 2021; Mach F et al., Atherosclerosis, 2025).

Special attention is due to lipoprotein(a) (or Lp(a)), whose level is largely determined by genetic factors and usually stays relatively stable throughout life. A high Lp(a) level is associated with a higher likelihood of atherosclerotic cardiovascular disease. A standard lipid panel cannot measure it, so a separate blood test is needed.

The updated 2025 European ESC/EAS guidelines advise considering Lp(a) measurement at least once in adulthood. This test may be especially important with a family history of early cardiovascular events or high Lp(a) (Mach F et al., Atherosclerosis, 2025).

For a comprehensive assessment of cardiovascular risk, the SCORE2 (used in people aged 40–69) and SCORE2-OP (aged 70 and over) algorithms are used, taking into account age, sex, smoking, systolic blood pressure and cholesterol levels to estimate the likelihood of fatal and non-fatal cardiovascular events over the next ten years. The result helps the doctor determine how intensive preventive measures should be and/or whether medication is needed (Visseren FLJ et al., European Heart Journal, 2021).

For more on why cardiovascular risk is not just a matter of cholesterol, see the article Cardiovascular disease is not only about “bad” cholesterol: what genetics says.

Glucose and HbA1c

Type 2 diabetes can remain undetected for a long time: glucose levels rise gradually, and characteristic symptoms do not always appear. Meanwhile, prolonged hyperglycemia gradually damages the blood vessels, kidneys, retina and nervous system. Early detection of carbohydrate metabolism disorders makes it possible to start preventive measures in time.

Three main methods are used to screen for prediabetes and type 2 diabetes: fasting plasma glucose, the glycated hemoglobin (HbA1c) test and the oral glucose tolerance test.

HbA1c reflects average blood glucose over the previous two to three months. Unlike a single glucose measurement, it shows carbohydrate metabolism over a longer period. However, HbA1c can be inaccurate in some types of anemia and in conditions that change red blood cell lifespan or affect hemoglobin structure. In such cases a doctor may prefer to measure plasma glucose (American Diabetes Association Professional Practice Committee, Diabetes Care, 2026).

According to ADA 2026 recommendations, screening for prediabetes and type 2 diabetes should begin at age 35. Earlier testing may be needed with overweight or obesity combined with additional risk factors. If results are normal, repeat testing is recommended at least every three years. When prediabetes is confirmed, careful annual monitoring is recommended.

It is important to distinguish screening from diagnosis: a single test result that meets the diagnostic criteria for diabetes, in the absence of unequivocal hyperglycemia, usually needs confirmation by repeat testing.

Tests such as fasting insulin and the HOMA-IR indexdo not replace these methods and are not mandatory screening tests for every man. Their use should match a specific clinical question.

For more on genetic differences in insulin sensitivity and type 2 diabetes risk, see the article Insulin sensitivity and type 2 diabetes risk: the genetic dimension.

Colorectal cancer: when to start screening

Colorectal cancer often develops gradually and may show no obvious signs in the early stages. One feature of this disease is that some precancerous growths, adenomatous polyps, can be found and removed before they become malignant. That is why screening can not only help detect cancer early but also prevent it.

Several methods are used for screening: 

  • fecal immunochemical test (FIT), which detects hidden blood in the stool,

  • colonoscopy, which allows direct examination of the lining of the colon, detection of polyps and, if necessary, their removal during the procedure.

According to USPSTF, adults without known risk factors for colorectal cancer are advised to start screening at age 45 and continue regularly until age 75, including with an annual fecal immunochemical test (FIT). A positive test requires further testing, usually colonoscopy. If a colonoscopy finds no abnormalities, the next one is usually done after ten years.

At ages 76–85, the decision to continue screening is made individually, taking into account general health, previous test results and expected benefit. With a family history of colorectal cancer, hereditary syndromes or inflammatory bowel disease, screening may be needed earlier and on a different schedule (US Preventive Services Task Force, JAMA, 2021).

Important! Blood in the stool, persistent changes in bowel habits, unexplained weight loss, anemia or prolonged abdominal pain require medical evaluation at any age. With such symptoms, do not wait for scheduled screening; see a doctor as soon as possible.

Laboratory tests: when more does not mean better

The number of tests in a checkup does not by itself determine the quality of prevention: what matters is whether specific tests help answer clinical questions and whether the results will affect later decisions.

Without symptoms, known risk factors or other clinical indications, fasting insulin, HOMA-IR, cortisol, testosterone, ferritin, homocysteine, vitamin D, thyroid antibodies or extended biochemical panels should not be automatically included in an annual checkup. Each of these tests has specific indications. For example, ferritin is measured to detect iron deficiency, including before anemia develops; cortisol, when adrenal dysfunction is suspected; vitamin D, when there are risk factors for deficiency or clinical signs of mineral metabolism and bone disorders. For generally healthy adults without complaints or specific indications, routine 25(OH)D testing is also not recommended (Demay MB et al., The Journal of Clinical Endocrinology & Metabolism, 2024).

A similar principle applies to thyroid function. There is not enough evidence to support universal screening of all adult men without complaints or symptoms. Measuring thyroid-stimulating hormone (TSH) is appropriate when there are symptoms, risk factors or other clinical grounds (US Preventive Services Task Force, JAMA, 2015).

Unsystematic ordering of extra tests can create a false sense of control over one's health. Random deviations from reference values do not always indicate disease, but often lead to repeat tests and unnecessary interventions. A rational checkup starts with an assessment of individual needs, not with the longest possible list of laboratory markers.

Automatic digital blood pressure monitor with a grey cuff next to a glass cup of tea on a light blue table.

Genetic data in assessing men's health

Clinical examinations show the body's current state — what is happening now: how the cardiovascular system works, whether there are carbohydrate metabolism disorders, what the lipid and hormone levels are. A genetic test shows which inherited features of an individual man's physiology may affect how biological systems work and shape susceptibility to certain conditions.

Family history helps identify possible hereditary patterns. For example, early cardiovascular disease, prostate cancer or colorectal cancer among close relatives can be grounds for additional assessment. However, family history is not always complete: a disease may not have appeared in earlier generations, or information about relatives may be unavailable (National Cancer Institute, Cancer Genetics Risk Assessment and Counseling (PDQ®), 2025). Moreover, the absence of known cases of certain diseases or health characteristics in the family does not rule out genetic susceptibility.

Genetic characteristics can be linked to different mechanisms of hereditary susceptibility to disease. In particular, it is important to distinguish rare pathogenic genetic variants from common genetic differences, whose combined effect is assessed with polygenic models.

Rare pathogenic variants can substantially increase the likelihood of certain diseases and cause hereditary syndromes. For example, pathogenic variants in the genes BRCA1 (BRCA1 DNA repair associated) and BRCA2 (BRCA2 DNA repair associated) are linked to increased hereditary susceptibility to a number of cancers, including prostate cancer. Identifying such variants requires appropriate clinical evaluation and, where indicated, genetic counseling.

Another approach is polygenic risk assessment (Polygenic Risk Score, PRS). Unlike testing a specific gene for a rare pathogenic variant, a PRS takes into account the combined contribution of a large number of common genetic variants, each of which usually has a small individual effect. Together they form a polygenic susceptibility to a particular disease or physiological trait (Kachuri L et al., Nature Reviews Genetics, 2024). To assess clinical risk, genetic data are considered together with age, blood pressure, laboratory values, lifestyle and other factors.

Thus, genetic testing and clinical examinations provide different kinds of information that complement each other and broaden the options for assessing an individual man's health.

Apixmed Prism genetic test “Men's Health”

DNA test “Men's Health” from Apixmed Prism covers 34 markers: 22 composite polygenic scores and 12 individual genetic variants in 9 genes.

Composite scores reflect the combined contribution of common genetic variants associated with particular diseases and physiological traits. Analysis of individual variants makes it possible to assess specific genetic differences relevant to the corresponding areas of health.

The report contains information on genetic predispositions related to metabolism, physiological processes and susceptibility to certain conditions. These data describe the inherited component of an individual health profile but do not reflect the body's current state and do not replace clinical tests: a lipid panel, blood pressure measurement, PSA testing and other examinations as medically indicated.

How to prepare for a men's health checkup

The first step is a visit to a family doctor. An extended checkup with dozens of tests should not be a goal in itself. First it is important to assess the man's current health, find out which tests have already been done, whether their results have changed over time and which additional checks are really needed.

Before the visit, gather information about:

  • Previous tests: results of lab tests, blood pressure measurements and other examinations over the past year or two. This helps the doctor assess not only individual values but also changes over time.
  • Family history: information on illnesses in parents, brothers, sisters and other close relatives. It is especially important to tell the doctor about early heart attacks and strokes in the family, cases of prostate cancer, colorectal cancer, diabetes and other diseases with a hereditary component.
  • Changes in health: persistent loss of libido, erectile dysfunction, unexplained weight change, reduced physical endurance, sleep problems or changes in urination — tell the doctor about such signs even if they do not cause significant discomfort.
  • Lifestyle: level of physical activity, diet, smoking, alcohol use and other habits — these factors affect cardiovascular and metabolic health and can change individual risks.

After the visit, the doctor will help determine which tests the man needs now, which can be postponed, when to repeat tests already done, and whether there are indications for specialized examinations or genetic testing in other areas of health.

A personal checkup plan for a man is not about repeating the same set of tests every year or monitoring every marker associated with men's health. The content of a men's health checkup and, accordingly, how often preventive examinations are done depend on age, current health, family history and the results of previous tests. This approach helps to detect changes in time, determine the need for further diagnostics and maintain a man's physical activity, functional capacity and quality of life over the years.

 

Genetic test results are not a diagnosis and not a substitute for a doctor's consultation. 

The Apixmed Prism report provides genetic context that complements test results and helps in making decisions together with a doctor.

 

Sources

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–263. DOI: 10.3322/caac.21834
  2. Wei JT, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. The Journal of Urology. 2023;210(1):46–53. DOI: 10.1097/JU.0000000000003491
  3. European Association of Urology. EAU Guidelines on Prostate Cancer. 2025. https://uroweb.org/guidelines/prostate-cancer
  4. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–1744. DOI: 10.1210/jc.2018-00229
  5. US Preventive Services Task Force. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2021;325(16):1650–1656. DOI: 10.1001/jama.2021.4987
  6. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337. DOI: 10.1093/eurheartj/ehab484
  7. Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479. DOI: 10.1016/j.atherosclerosis.2025.120479
  8. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. DOI: 10.2337/dc26-S002
  9. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. DOI: 10.1001/jama.2021.6238
  10. Demay MB, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907–1947. DOI: 10.1210/clinem/dgae290
  11. US Preventive Services Task Force. Screening for Thyroid Dysfunction: US Preventive Services Task Force Recommendation Statement. JAMA. 2015;313(5):457–464. DOI: 10.1001/jama.2015.0233
  12. National Cancer Institute. Cancer Genetics Risk Assessment and Counseling (PDQ®) – Health Professional Version. 2025. https://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq
  13. Kachuri L, Chatterjee N, Hirbo J, et al. Principles and methods for transferring polygenic risk scores across global populations. Nature Reviews Genetics. 2024;25(1):8–25. DOI: 10.1038/s41576-023-00637-2

Any questions left?

Leave your contact details — our specialists will contact you shortly. We will help you understand the offers, select a test according to your request, and answer any questions about the product and process.